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Abstract: Early recognition of prostate cancer (PC) based on biological markers could be helpful in identifica-
tion of differences in benign and malignant lesions and facilitate further precise indication for more aggressive
treatment. Therefore, the aim of our study was to assess expression of hTERT (human telomerase reverse
transcriptase, a catalytic subunit of telomerase) and prostate-specific membrane antigen (PSMA), both consid-
ered to be markers of tumor aggressiveness. 140 low advanced PC specimens from patients who underwent
radical prostatectomy were studied. Protein expression was assessed immunohistochemically on tumor sections
and expressed as labeling index (LI), i.e. the percentage of positively stained cells. In case of telomerase, only
nuclear staining and in case of PSMA, membrane and cytoplasmic staining, were considered as positive. The
mean age of the patients was 62.9 ± 6.2 years. There were 75 (53.6%) well differentiated tumors (Gleason score
  6), 52 (37.1%) moderately differentiated tumors (Gleason score of 7) and 13 (9.3%) poorly differentiated
tumors (Gleason score 8-10). The mean pre-operative serum PSA was 9.9 ± SE 5.5 ng/mL, and the mean LI
were 18.0 ± 1.5% and 44.1 ± 1.9%, for hTERT and PSMA, respectively. With increase of pathological tumor stage
and tumor grade statistically significant increase of PSA serum concentration (P < 0.011) and PSMA (P < 0.004)
expression was noticed, however, for expression of telomerase the relation was opposite one. The observed in
higher pTNM stages and tumor grades decrease in nuclear expression of hTERT was caused by translocation
of the subunit to the cytoplasm, what may indicate extranuclear telomerase activity independent of telomere
lengthening, hence, it cannot be considered as a marker of malignancy. Higher PSMA expression in higher
pTNM stages and tumor grades suggest that PSMA may be a good marker of biological aggressiveness suitable
for patients’ selection for more aggressive treatment. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 1,
66–72)
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Introduction
Late prostate cancer (PC) recognition is the main
cause of treatment failure, similarly as in other neo-
plastic diseases. Earlier recognition based on biolog-
ical markers could be helpful in identification of bio-
logical differences in benign and malignant lesions,
what could further help in precise indication for more
aggressive post-operative treatment (chemo/radio-
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therapy). Prostate specific antigen (PSA) is now com-
monly regarded as an indicator of prostate cancer
stage and cannot be regarded as an independent di-
agnostic or prognostic factor in prostate cancer as
determinations of PSA serum levels have limitations
— lack of specificity, elevation in benign disease and
failure to detect a number of PSA-negative tumors
[1]. Despite the considerable attention given to PSA
as a screening test, the standard method for diagnos-
ing PC is a transrectal ultrasound (TRUS) guided
prostate biopsy. Unfortunately, conventional biopsy
protocols have been found to have unacceptable high
false-negative rates [2]. The contrast enhanced color
Doppler ultrasound targeted biopsy and the magnet-
ic resonance imaging have been devised to increase
the specificity of the PC detection, however, these
methods still present considerable rates of false-pos-
itive and false-negative results [3]. Thus, PC diagno-
sis in men with persistently increased PSA after
a negative initial TRUS guided biopsy has become
a great challenge for urologists and pathologists.
Therefore, better prognostic markers are needed,
which would allow for the differentiation between
benign and malignant cases [4].
It was suggested that detection of telomerase pres-
ence might be one of such markers. Telomerase is
a ribonucleoprotein enzyme that adds telomeric re-
peats (TTAGGG) into chromosomal ends using
a segment of its own RNA component (hTR) as
a template. Its catalytic subunit, reverse transcriptase
component (hTERT), controls its activity and its ex-
pression is restricted to the cells that demonstrate te-
lomerase activity [5]. Because of its ability to immor-
talize cancer cells, it plays a significant role in tumor
growth [6]. Previously it was shown that telomerase
was activated in a large majority of human cancer tis-
sues, however, not in most normal tissues or in tis-
sues adjacent to malignant or benign tumors [6].
Therefore, it was suggested that telomerase activity
can be a useful marker for cancer detection [7]. It
was also found that telomerase activity was detected
in approximately 90% of human cancer tissues [6, 8,
9], and the level of telomerase activity correlated with
prostate cancer pathologic grade, suggesting that te-
lomerase activity may be a marker of tumor’s malig-
nant potential [10–12].
Apart from tumor biopsy, telomerase activity and/
or hTERT expression was also detected in clinical
materials such as body fluids, secretions, washes,
brushings, blood, and fine needle aspirates [7]. To
detect cell telomerase activity, different methods have
been applied: in situ telomeric repeat amplification
protocol (TRAP assay), the RT-polymerase chain
reaction (PCR) of mRNA and hTERT immunohis-
tochemistry. However, recent evidence shows that
telomerase might play novel, extratelomeric roles,
unrelated to the telomere length regulation in medi-
ating cell survival and anti-apoptotic functions against
various cytotoxic stresses which can have potentially
important biological consequences, particularly in
cancer cells [13, 14]. Furthermore, it was demonstrat-
ed, that hTERT regulates transcriptional activity of
a key cell cycle regulator, cyclin D1 [15].
Prostate-specific membrane antigen (PSMA) is
a membrane protein expressed in all forms of prostate
tissue, including carcinoma [16]. In contrast to other
highly restricted prostate-related antigens such as PSA
and prostatic acid phosphatase, which are secretory
proteins, PSMA is an integral cell membrane protein.
The PSMA protein has three major domains: inter-
nal, transmembrane and extracellular parts [17] and
acts as a glutamate-preferring carboxypeptidase [18].
Although PSMA is primarily expressed in normal
human prostate epithelium, it was found to be upreg-
ulated and strongly expressed in prostate cancer cells,
including those of the metastatic state [19]. Immuno-
histochemical staining revealed a correlation between
PSMA expression and severity of cancer [19]. PSMA
expression allows for the identification of benign and
malignant prostatic epithelium and may be a poten-
tially valuable marker in the treatment of patients with
prostate cancer [20].
PSMA has an internalization signal that allows for
the internalization of the protein on the cell surface,
which makes it a useful antigenic target for therapy
and diagnosis [21–23]. Till now, no correlation of te-
lomerase or PSMA activity with preoperative serum
PSA concentrations or pathologic data, including tu-
mor grade and stage has been established. Therefore,
we sought to evaluate their potential role as immuno-
histochemical diagnostic markers for patients with PC.
Material and methods
Patients. The study involved evaluation of 140 consecutive
radical prostatectomy specimens, obtained from patients
who underwent radical prostatectomy for localized PC be-
tween 2007 and 2011. The mean age of the patients was
62.9 ± 6.2 years. Clinical staging was carried out according
to American Joint Committee on Cancer (AJCC) and the
International Union Against Cancer [24]. Grading was es-
tablished according to the Gleason score (GS) differentia-
tion system (range 2–10) [25]. Patients were divided into
three Gleason score groups according to American Joint
Committee on Cancer (AJCC): well differentiated (Glea-
son score   6), moderately differentiated tumors (Gleason
score of 7) and poorly differentiated tumors (Gleason score
8–10). The protocol was approved by the Ethical Commit-
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tee of the Center of Oncology, and each patient submitted
written consent.
Immunohistochemical assessment of tumor markers. Fol-
lowing rehydration, in 5 µm sections heat-based antigen re-
trieval was carried out (for telomerase, 30 min at 96oC with
Target Retrieval Solution, pH 9.0, for PSMA 20 min, pH
6.0). After cooling for 20 minutes, endogenous peroxidases
were blocked using 0.3% hydrogen peroxide in 100% meth-
anol. Next, the sections were washed, flooded with 2.5%
normal horse blocking serum for 20 min and incubated with
proper antibody overnight at 4oC. For hTERT it was a rab-
bit polyclonal antibody to human telomerase (Novus Lab.
Biologicals, Littleton, USA), (1:300), and for PSMA it was
a mouse anti-human prostate specific membrane antigen
(Novocastra, Newcastle, United Kingdom) (1:200). After
washing, slides were incubated in room temperature for 1 h
with ImmPRESS Reagent Kit visualization system contain-
ing proper antibody (VECTOR LAB, Inc, Burlingame,
USA). The sections were stained with diaminobenzidine
(DAB), counterstained with hematoxylin, dehydrated and
mounted. Negative control slides omitting the primary an-
tibody were included in each run of stains. The positive con-
trol for anti-TERT was squamous cell esophageal carcino-
ma, while for PSMA — benign hypertrophic prostatic glands
served as an internal control. The intensity of immunostain-
ing was evaluated by light microscopy at 400 × (hTERT) and
200 × (PSMA) magnification. For telomerase, only diffuse
nuclear or diffuse nuclear with nucleolar accentuation was
considered as positive staining (Figure 1A); cytoplasmic
hTERT immunoreactivity (Figure 1B) was regarded as neg-
ative. For PSMA, immunoreactivity was identified as mem-
brane staining (extracellular portion of the antigen) (Fig-
ure 1C) with two different patterns of positive staining in-
cluding apical and/or apical and cytoplasmic. The binding
occurred in the epithelial cells of the prostate but not in the
basal or stromal cells (Figure 1D). Nonhyperplastic and
benign hyperplastic acini were not evaluated. Protein ex-
pression was shown in the form of labeling indices (LI) in-
terpreted as a percentage of positively immunostained cells
(brown). About 500–1000 cells were counted in several
(4–6) malignant areas of tissue sections.
Statistical analysis. Statistical analysis was performed with
STATISTICA ver. 9. Intergroup differences in the original
data were tested with ANOVA test or Student’s t test. P
Figure 1. Immunohistochemical localizations of telomerase and PSMA in prostate cancer (PC). (A) Diffuse nuclear
hTERT staining (positive, arrow) in low-differentiated and (B) cytoplasmic (not analyzed) staining in moderately-
differentiated PC. (C) Strong PSMA immunoreactivity in infiltrating low-differentiated and (D) moderately differentiated
PC. Note negative staining in the hyperplastic acini
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values of less than 0.05 were considered to indicate statisti-
cal significance.
Results
We examined human histological specimens from
140 PC patients treated with radical surgery. There
were 13 patients (9.3%) at pTNM stage 1, 78 (55.7%)
at stage 2, 40 (28.6%) at stage 3 and 9 (6.4%) at stage
4, respectively. In the analyzed group there were
75 (53.6%) well differentiated, 52 (37.1%) moderately
differentiated and 13 (9.3%) poorly differentiated
tumors. Pre-operative PSA revealed a median PSA
of 9.9 ± 5.5 ng/mL. Concentration of serum PSA was
significantly increased with pTNM stage (P = 0.011),
Gleason score (P = 0.002), and tumor grade (P = 0.003).
In the three grade groups, nuclear reactivity of
hTERT was present in 81% of sections and the mean
LITERT was equal to 18.0±1.5%. Expression of hTERT
significantly decreased with tumor grade (P = 0.025,
Figure 2). The mean LI hTERT percentages for low to
high-grade groups were 21.1%, 16.1% and 7.3%, respec-
tively. The number of positively staining hTERT cells
was not correlated with Gleason score (P = 0.142)
and pathological tumor stage (p = 0.311). In higher
tumor grade, more frequently negative nuclear
hTERT staining and positive hTERT localization in
the cytosol was observed, and this form of staining
was not taken into consideration.
For PSMA staining, in benign epithelium, weak
cytoplasmic heterogeneous immunoreactivity was
observed, however, only tumor cells were evaluated.
The mean LIPSMA was 44.1 ± 1.9%. However, oppo-
site results than in case of telomerase were observed.
A positive correlation was demonstrated between the
PSMA expression and Gleason score (P = 0.003).
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Figure 2. Association between telomerase immunoreactivity (LIhTERT) and (A) pathological tumor stage (pTNM) or (B)
tumor grade in prostate cancer. Symbols represent mean values ± SE
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Figure 3. Association between PSMA expression (LIPSMA) and (A) pathological tumor stage (pTNM) or (B) tumor grade
in prostate cancer. Symbols represent mean values ± SE
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Also PSMA expression statistically significantly cor-
related with pTNM stage (P = 0.022, Figure 3A) and
grade (P = 0.005, Figure 3B). The mean LIPSMA value
for low-grade PC was 37.5%, for moderately differ-
entiated tumors 51.3% and 53.9% for poorly differ-
entiated tumors.
Discussion
We studied expression of two proteins thought to be
prognostic biomarkers of malignancy in PC. This opin-
ion can be true in case of PSMA for which we ob-
served significant increase of expression with tumor
stage and grade, whereas for telomerase, such a cor-
relation was not found and therefore it cannot be
considered as a good malignancy marker in PC. In
our series, significant decrease of telomerase immu-
noreactivity (nuclear localization) with the tumor
grade and tendency to lower values with tumor stage
was observed. This was caused in high-grade tumors
by translocation of positive hTERT staining from the
nucleus, where its activity is connected with telomere
maintenance, to the cytosol. As cytoplasmic hTERT
activity is extratelomeric, this localization was not tak-
en into consideration in our study. We used the same
criteria as other authors analyzing earlier hTERT
activity in PC where nucleolar /nuclear localization
was considered as positive, whereas all cytoplasmic
reactivity was regarded as negative [11]. It was shown
earlier that telomerase activation occurs in the
progress of carcinogenesis, hTERT mRNA was cyto-
plasmic and TERT protein was mainly found in the
nucleus, indicating that TERT protein produced by
the transcription of mRNA in the cytoplasm becomes
localized in the nucleus [11]. However, our results
contradict the studies based also on immunohis-
tochemistry showing the greater percentage of
hTERT positive cells in high-grade than low-grade
prostatic cancers [11, 26] and displaying stronger
hTERT activity in higher cancer stages [12]. In our
study, the relation was reverse. We observed non-sig-
nificant decrease in the immunoreactivity of the en-
zyme with pathological stage and Gleason score, what
may be in agreement with the findings of others [9,
27]. Additionally, in our study, the mean LI hTERT for
different grade groups was two-times [11] and three-
times [26] lower than in the studies of other authors
what indicates that the results are controversial. The
reason for this discrepancy might be not only meth-
odological differences: different monoclonal antibod-
ies used and the different number of analyzed tumors
(much smaller number of high-grade tumors in our
study), but also the fact that some telomerase func-
tions were not fully recognized at that time.
Recently, a new aspect of telomerase activity, in-
dependent of telomeres lengthening has emerged to
explain its protective effects on cell survival and stress
resistance [13]. The observation that TERT resides
not only in the nucleus, but also in the cytosol, rein-
forces the notion of possible telomere-independent
functions [13]. It has been suggested that telomerase
in the cytoplasm protects mitochondria from oxida-
tive stress [28] and performs other extratelomeric
functions like enhancing cell viability under condi-
tions of environmental stress such as hypoxia [29].
Telomerase has been shown to shuttle dynamically
between different cellular locations. Under increased
oxidative stress, telomerase is excluded from the nu-
cleus and can be found within the mitochondria [30]
that seem to be unrelated to telomere maintenance.
This phenotype (with cytoplasmic TERT localization)
correlates with decreased oxidative stress and im-
proved mitochondrial function by currently largely
unknown mechanisms [28–30]. These data correlate
with pro-survival and anti-apoptotic functions of te-
lomerase. This may be in agreement with our results
obtained in the analysis of the same group of tumors
showing high proliferative potential (based on Ki-67)
and active glycolytic metabolism (GLUT-1 expres-
sion) in high-grade PC tumors [31]. Although our
understanding of the underlying mechanisms is lim-
ited and the biological significance of these process-
es requires further investigation, the data add to the
already established non-canonical functions of telom-
erase that correlate with its extra-nuclear localization.
Nowadays, it is considered that transport of hTERT
to the mitochondria seems to be an induced, directed
and naturally occurring process [30]. According to
Maser et al. [32] telomerase is located within the nu-
cleolus or the cytoplasm and only gets targeted to the
telomere during replication. All these observations
suggest that those novel telomerase functions work
by mechanisms that are separated from normal te-
lomere lengthening and capping, considered in the
past to be the main feature of malignancy. Therefore,
these, not yet sufficiently known, extra-telomeric te-
lomerase functions, independent of catalytic activity,
require establishing new assessment criteria of the
enzyme«s immunoreactivity before it is recommend-
ed as a marker of malignancy in clinical setting.
Androgens play a central role in prostate develop-
ment and prostate cancer proliferation [33]. Several re-
ports suggest that telomerase activity is regulated by
androgens in vivo and low androgen level might create
problems with translocation of hTERT protein from
cytoplasm to the nucleus [33, 34]. This may be in agree-
ment with the study showing that androgen ablation re-
duces telomerase most dramatically in the highest grade
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malignancies [35] and decreases PSA serum levels be-
cause testosterone which is required to drive produc-
tion of PSA is surgically or medically eliminated [36].
In our study, concentration of serum PSA posi-
tively correlated with pTNM stage, Gleason score, and
tumor grade. PSA is a glycoprotein secreted into the
lumen of prostatic glands to liquefy the seminal co-
agulation. In invasive adenocarcinomas, disruption of
the normal glandular architecture and loss of the po-
larity of prostatic cells appear to allow increased di-
rect PSA diffusion to prostate gland vessels.
In the present study, the increased expression of
PSMA correlated significantly with higher preopera-
tive PSA levels, high tumor grade and advanced tu-
mor stage. Although PSA and PSMA are regulated
differentially, their expression showed a correlation
with malignant transformation. In our series, the ex-
pression of PSMA was significantly greater in higher
tumor advancement and grade and was larger than
that of PSA in poorly differentiated tumors, which
confirms earlier studies [19]. Our finding is consis-
tent with previous reports using immunohistochem-
istry and multiplex PCR reaction to demonstrate the
association between PSMA and tumor progression
[37, 38]. The mean LIPSMA value in our study was
44.1% and was within the range (30–100%) given by
different authors [19, 20, 36, 37]. The difference in
the mean values might be caused by non-equal num-
ber of cases in the analyzed tumor grade groups (val-
ue ranges were similar).
In normal and hyperplastic prostate epithelium we
observed weak and heterogeneous positive PSMA
expression which is in agreement with other authors’
observations [19, 20, 27]. In normal prostate tissue,
the dominating form of this protein is the one that
appears in the cytoplasm. However, in PC cells PSMA
expression was mainly membranous. Low expression
in normal hyperplastic tissue would suggest a limited
role of PSMA in normal human prostate or hyper-
plastic tissue. It was shown that PSMA expression was
negatively regulated by androgen levels [36]. The in-
creased expression of PSMA in poorly differentiated
tumors suggests that this protein may be associated
with development of hormone-independent prostate
cancers [36]. Furthermore, the enhanced expression
of PSMA occurs after androgen deprivation what sug-
gests that PSMA is upregulated in the majority of PC
after androgen treatment. Therefore, assessment of
PSMA expression may be helpful in indication for
more aggressive treatment (chemo-/radiotherapy).
The prostate-restricted nature of PSMA, coupled
with the direct association between the level of PSA
expression and increasingly aggressive disease, implies
a potentially important role of PSMA in PC biology.
This may confirm the study of Rajasekaran and co-
workers [39] who indicated that PSMA has a causal
role in the induction of aneuploidy and might play an
etiologic role in the PC progression.
PSMA, as an integral membrane protein highly
specific for prostate, may prove to be effective as
a target for imaging and cytotoxic targeting modalities
[23, 40]. Monoclonal antibodies may be internalized
by PC cells [21]. The availability of prostate-specific
internalizing antibodies should aid the development
of novel therapeutic methods to target the delivery
of toxins, drugs, or short-range isotopes specifically
to the interior of prostate cancer cells [22, 23, 40].
The high expression in metastatic tissues strongly sug-
gests that PSMA may be a clinically useful target for
antibody and genetic-directed therapy of PC that re-
curs after androgen deprivation [36].
Conclusions
Our data confirm that PSMA expression allows the
identification of benign and malignant prostatic epi-
thelium and may be a potentially valuable marker in
the treatment of prostatic cancer. The export of
hTERT from nucleus to the cytoplasm observed in
high grade PC may suggest that telomerase plays
a different role than telomere lengthening in prostate
cancer. Before the assessment criteria are established,
evaluation of hTERT immunoreactivity cannot be
recommended as a biomarker of malignancy.
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